Background: Iodine deficiency disorders (IDD) represent a global health threat to individuals and societies. IDD prevention programmes have been introduced in many parts of the world. However, challenges remain, particularly in Europe due to fragmentation and diversity of approaches that are not harmonized. Objectives: This review is dedicated to the public-health impact of IDD prevention programmes. It sums up experiences collected by the EUthyroid consortium so far and provides information on stakeholders that should be involved in actions directed to improve the impact of IDD prevention. Methods: A joint European database for combining registry-based outcome and monitoring data as well as tools for harmonizing study methods were established. Methods for analyzing thyroglobulin from a dried blood spot are available for assessing the iodine status in the general population and at-risk groups. Mother-child cohorts are used for in-depth analysis of the potential impact of mild-to-moderate iodine deficiency on the neurocognitive development of the offspring. A decision-analytic model has been developed to evaluate the long-term effectiveness and cost effectiveness of IDD prevention programmes. Results: EUthyroid has produced tools and infrastructure to improve the quality of IDD monitoring and follows a dissemination strategy targeting policymakers and the general public. There are tight connections to major stakeholders in the field of IDD monitoring and prevention. Conclusions: EUthyroid has taken steps towards achieving a euthyroid Europe. Our challenge is to inspire a greater sense of urgency in both policymakers and the wider public to address this remediable deficit caused by IDD.

Keywords:
Iodine, Prevention, Epidemiology, Outcomes research
2.
Laurberg P, Pedersen KM, Hreidarsson A, Sigfusson N, Iversen E, Knudsen PR: Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. J Clin Endocrinol Metab 1998; 83: 765–769.
3.
Völzke H, Lüdemann J, Robinson DM, Spieker KW, Schwahn C, Kramer A, John U, Meng W: The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003; 13: 803–810.
4.
Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Åsvold BO, Sgarbi JA, Völzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N; Thyroid Studies Collaboration: Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172: 799–809.
5.
Zimmermann MB: Research on iodine deficiency and goiter in the 19th and early 20th centuries. J Nutr 2008; 138: 2060–2063.
6.
The EUthyroid Consortium: The Krakow Declaration on Iodine: Tasks and responsibilities for prevention programs targeting iodine deficiency disorders. Eur Thyroid J 2018;7:201–204.
7.
Völzke H, Caron P, Dahl L, de Castro JJ, Erlund I, Gaberšček S, Gunnarsdottir I, Hubalewska-Dydejczyk A, Ittermann T, Ivanova L, Karanfilski B, Khattak RM, Kusić Z, Laurberg P, Lazarus JH, Markou KB, Moreno-Reyes R, Nagy EV, Peeters RP, Pīrāgs V, Podoba J, Rayman MP, Rochau U, Siebert U, Smyth PP, Thuesen BH, Troen A, Vila L, Vitti P, Zamrazil V, Zimmermann MB: Ensuring effective prevention of iodine deficiency disorders. Thyroid 2016; 26: 189–196.
8.
Ittermann T, Johner S, Below H, Leiterer M, Thamm M, Remer T, Völzke H: Interlaboratory variability of urinary iodine measurements. Clin Chem Lab Med 2018; 56: 441–447.
9.
Zimmermann MB, Andersson M: Assessment of iodine nutrition in populations: past, present, and future. Nutr Rev 2012; 70: 553–570.
10.
Zimmermann MB, de Benoist B, Corigliano S, Jooste PL, Molinari L, Moosa K, Pretell EA, Al-Dallal ZS, Wei Y, Zu-Pei C, Torresani T: Assessment of iodine status using dried blood spot thyroglobulin: development of reference material and establishment of an international reference range in iodine-sufficient children. J Clin Endocrinol Metab 2006; 91: 4881–4887.
11.
Karmisholt J, Laurberg P, Andersen S: Recommended number of participants in iodine nutrition studies is similar before and after an iodine fortification programme. Eur J Nutr 2014; 53: 487–492.
12.
Golding J; ALSPAC Study Team: The Avon Longitudinal Study of Parents and Children (ALSPAC) – study design and collaborative opportunities. Eur J Endocrinol 2004; 151(suppl 3):U119–U123.
13.
Valera-Gran D, Navarrete-Muñoz EM, Garcia de la Hera M, Fernández-Somoano A, Tardón A, Ibarluzea J, Balluerka N, Murcia M, González-Safont L, Romaguera D, Julvez J, Vioque J; INMA Project: Effect of maternal high dosages of folic acid supplements on neurocognitive development in children at 4–5 y of age: the prospective birth cohort Infancia y Medio Ambiente (INMA) study. Am J Clin Nutr 2017; 106: 878–887.
14.
Kooijman MN, Kruithof CJ, van Duijn CM, Duijts L, Franco OH, van IJzendoorn MH, de Jongste JC, Klaver CC, van der Lugt A, Mackenbach JP, Moll HA, Peeters RP, Raat H, Rings EH, Rivadeneira F, van der Schroeff MP, Steegers EA, Tiemeier H, Uitterlinden AG, Verhulst FC, Wolvius E, Felix JF, Jaddoe VW: The Generation R Study: design and cohort update 2017. Eur J Epidemiol 2016; 31: 1243–1264.
15.
Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem D, Brixner D, Radich J, Gastl G, Siebert U: Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma 2015; 56: 2315–2325.
16.
Dunn JT: Complacency: the most dangerous enemy in the war against iodine deficiency. Thyroid 2000; 10: 681–683.
17.
Zimmermann MB: The effects of iodine deficiency in pregnancy and infancy. Paediatr Perinat Epidemiol 2012; 26(suppl 1): 108–117.
18.
O’Kane SM, Pourshahidi LK, Mulhern MS, Weir RR, Hill S, O’Reilly J, Kmiotek D, Deitrich C, Mackle EM, Fitzgerald E, Lowis C, Johnston M, Strain JJ, Yeates AJ: The effect of processing and seasonality on the iodine and selenium concentration of cow’s milk produced in Northern Ireland (NI): implications for population dietary intake. Nutrients 2018; 10:pii:E287.
19.
Andersen S, Noahsen P, Westergaard L, Laurberg P: Reliability of thyroglobulin in serum compared with urinary iodine when assessing individual and population iodine nutrition status. Br J Nutr 2017; 117: 441–449.
20.
Marangoni F, Cetin I, Verduci E, Canzone G, Giovannini M, Scollo P, Corsello G, Poli A: maternal diet and nutrient requirements in pregnancy and breastfeeding. An Italian consensus document. Nutrients 2016; 8:pii:E629.
21.
Møllehave LT, Linneberg A, Skaaby T, Knudsen N, Ehlers L, Jørgensen T, Thuesen BH: Trends in Costs of Thyroid Disease Treatment in Denmark during 1995–2015. Eur Thyroid J 2018; 7: 75–83.
22.
European Food Safety Authority (EFSA): Scientific opinion on dietary reference values for iodine. EFSA J 2014; 12: 3660.
23.
Bath SC, Sleeth ML, McKenna M, Walter A, Taylor A, Rayman MP: Iodine intake and status of UK women of childbearing age recruited at the University of Surrey in the winter. Br J Nutr 2014; 112: 1715–1723.
24.
Vanderpump MP, Lazarus JH, Smyth PP, Laurberg P, Holder RL, Boelaert K, Franklyn JA; British Thyroid Association UK Iodine Survey Group: Iodine status of UK schoolgirls: a cross-sectional survey. Lancet 2011; 377: 2007–2012.
25.
Lampropoulou M, Lean M, Combet Aspray E: Iodine status of women of childbearing age in Scotland. Proc Nutr Soc 2012; 71:E143.
© 2018 European Thyroid Association Published by S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.